Search

Displaying results 2231 - 2240 of 4575 in total
  1. Drug

    Echinacoside

    go.drugbank.com/drugs/DB15488
    Investigational

    Echinacoside is a phenylethanoid glycoside isolated from Echinacea angustifolia in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis, acute colitis, wound treatment, and h...

  2. Drug

    Tenofovir disoproxil

    go.drugbank.com/drugs/DB00300
    ApprovedInvestigational

    Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name _Viread_, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase

  3. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available. … [L2615] Dandruff is a common scalp disease affecting >40% of the world's adult population, and may be caused by fungi such as _Malassezia globosa_ and _M. restricta_.[A32162]

  4. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    Fostamatinib has also been granted orphan drug status by the FDA [L2644].

  5. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because it can prevent estrogen deficiency-induced bone loss without causing uterine hypertrophy.

  6. Drug

    Bismuth subsalicylate

    go.drugbank.com/drugs/DB01294
    ApprovedVet approved

    Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. … [A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort.

  7. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  8. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  9. Drug

    Nitrofurantoin

    go.drugbank.com/drugs/DB00698
    ApprovedInvestigationalVet approved

    [L6856,L6859,L6862] Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein.

  10. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism